Merck initiates Phase 3 trials for four investigational candidates

Merck announced the initiation of pivotal Phase 3 trials for four of its investigational candidates from its diverse pipeline in hematologic malignancies and solid tumors. Global Phase 3 studies have been initiated and are actively enrolling for the following investigational candidates: Bomedemstat, an investigational orally available lysine-specific demethylase 1 inhibitor, being evaluated for the treatment of certain patients with essential thrombocythemia; Nemtabrutinib, an investigational oral, reversible, non-covalent Bruton’s tyrosine kinase inhibitor, being evaluated for the treatment of certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma; MK-2870, an investigational trophoblast cell-surface antigen 2-directed antibody drug conjugate being developed in collaboration with Kelun-Biotech, which is being evaluated for certain patients with non-small cell lung cancer and certain patients with previously treated endometrial carcinoma; and MK-5684, an investigational CYP11A1 inhibitor being developed in collaboration with Orion, which is being evaluated for the treatment of certain patients with metastatic castration-resistant prostate cancer.